Autophagy Plays a Role in the CUL4A-Related Poor Prognosis of Intrahepatic Cholangiocarcinoma

CUL4A regulate the termination of autophagy in a physical process. However, the relationship between CUL4A and autophagy in cancer is unclear. We retrospectively investigated 99 intrahepatic cholangiocarcinoma (iCCA) cases. Whole sections were used for immunohistochemical analysis for p62, and LC3B...

Full description

Saved in:
Bibliographic Details
Published inPathology oncology research Vol. 27; p. 602714
Main Authors Weng, Shao-Wen, Liu, Ting-Ting, Eng, Hock-Liew, You, Huey-Ling, Huang, Wan-Ting
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media SA 23.02.2021
Frontiers Media S.A
Subjects
Online AccessGet full text
ISSN1532-2807
1219-4956
1532-2807
DOI10.3389/pore.2021.602714

Cover

Abstract CUL4A regulate the termination of autophagy in a physical process. However, the relationship between CUL4A and autophagy in cancer is unclear. We retrospectively investigated 99 intrahepatic cholangiocarcinoma (iCCA) cases. Whole sections were used for immunohistochemical analysis for p62, and LC3B expression. Q-score was defined as the sum of the labeling intensity and proportion. The cut-off point for immunoreactivity was set. CUL4A was overexpressed in cell lines and autophagy reflux was compared after manipulation. The iCCA cases with CUL4A overexpression had significantly higher prevalence of intact activated autophagy (42.4 vs. 15.2%; p = 0.003), which was significantly associated with advance tumor stage (34.1% vs. 15.4%; p = 0.032), less extensive necrosis (8.3 vs. 49.3%; p < 0.001), and shortened disease-free survival (mean, 19.6 vs. 65.5 months, p = 0.015). In vitro , iCCA cells with CUL4A overexpression significantly increased LC3II level as compared to the cells under basal condition. Although both cell types showed intact autophagy with increased LC3II expression after bafilomycin A1 treatment, the accumulation of LC3II was higher in CUL4A-overexpressing cells. CUL4A overexpression increased the proliferation of cells as compared with control cells. After treatment with bafilomycin A1, proliferation was inhibited in both cell types, but the effects were more prominent in the cells overexpressing CUL4A. CUL4A promotes autophagy, and exhibits significantly higher autophagic flux which affects the proliferation of iCCA cells; these effects correlated with advance tumor stage and poor prognosis. Thus, targeting autophagy may be potentially therapeutic in iCCA.
AbstractList CUL4A regulate the termination of autophagy in a physical process. However, the relationship between CUL4A and autophagy in cancer is unclear. We retrospectively investigated 99 intrahepatic cholangiocarcinoma (iCCA) cases. Whole sections were used for immunohistochemical analysis for p62, and LC3B expression. Q-score was defined as the sum of the labeling intensity and proportion. The cut-off point for immunoreactivity was set. CUL4A was overexpressed in cell lines and autophagy reflux was compared after manipulation. The iCCA cases with CUL4A overexpression had significantly higher prevalence of intact activated autophagy (42.4 vs. 15.2%; p = 0.003), which was significantly associated with advance tumor stage (34.1% vs. 15.4%; p = 0.032), less extensive necrosis (8.3 vs. 49.3%; p < 0.001), and shortened disease-free survival (mean, 19.6 vs. 65.5 months, p = 0.015). In vitro , iCCA cells with CUL4A overexpression significantly increased LC3II level as compared to the cells under basal condition. Although both cell types showed intact autophagy with increased LC3II expression after bafilomycin A1 treatment, the accumulation of LC3II was higher in CUL4A-overexpressing cells. CUL4A overexpression increased the proliferation of cells as compared with control cells. After treatment with bafilomycin A1, proliferation was inhibited in both cell types, but the effects were more prominent in the cells overexpressing CUL4A. CUL4A promotes autophagy, and exhibits significantly higher autophagic flux which affects the proliferation of iCCA cells; these effects correlated with advance tumor stage and poor prognosis. Thus, targeting autophagy may be potentially therapeutic in iCCA.
CUL4A regulate the termination of autophagy in a physical process. However, the relationship between CUL4A and autophagy in cancer is unclear. We retrospectively investigated 99 intrahepatic cholangiocarcinoma (iCCA) cases. Whole sections were used for immunohistochemical analysis for p62, and LC3B expression. Q-score was defined as the sum of the labeling intensity and proportion. The cut-off point for immunoreactivity was set. CUL4A was overexpressed in cell lines and autophagy reflux was compared after manipulation. The iCCA cases with CUL4A overexpression had significantly higher prevalence of intact activated autophagy (42.4 vs. 15.2%; p = 0.003), which was significantly associated with advance tumor stage (34.1% vs. 15.4%; p = 0.032), less extensive necrosis (8.3 vs. 49.3%; p < 0.001), and shortened disease-free survival (mean, 19.6 vs. 65.5 months, p = 0.015). In vitro, iCCA cells with CUL4A overexpression significantly increased LC3II level as compared to the cells under basal condition. Although both cell types showed intact autophagy with increased LC3II expression after bafilomycin A1 treatment, the accumulation of LC3II was higher in CUL4A-overexpressing cells. CUL4A overexpression increased the proliferation of cells as compared with control cells. After treatment with bafilomycin A1, proliferation was inhibited in both cell types, but the effects were more prominent in the cells overexpressing CUL4A. CUL4A promotes autophagy, and exhibits significantly higher autophagic flux which affects the proliferation of iCCA cells; these effects correlated with advance tumor stage and poor prognosis. Thus, targeting autophagy may be potentially therapeutic in iCCA.CUL4A regulate the termination of autophagy in a physical process. However, the relationship between CUL4A and autophagy in cancer is unclear. We retrospectively investigated 99 intrahepatic cholangiocarcinoma (iCCA) cases. Whole sections were used for immunohistochemical analysis for p62, and LC3B expression. Q-score was defined as the sum of the labeling intensity and proportion. The cut-off point for immunoreactivity was set. CUL4A was overexpressed in cell lines and autophagy reflux was compared after manipulation. The iCCA cases with CUL4A overexpression had significantly higher prevalence of intact activated autophagy (42.4 vs. 15.2%; p = 0.003), which was significantly associated with advance tumor stage (34.1% vs. 15.4%; p = 0.032), less extensive necrosis (8.3 vs. 49.3%; p < 0.001), and shortened disease-free survival (mean, 19.6 vs. 65.5 months, p = 0.015). In vitro, iCCA cells with CUL4A overexpression significantly increased LC3II level as compared to the cells under basal condition. Although both cell types showed intact autophagy with increased LC3II expression after bafilomycin A1 treatment, the accumulation of LC3II was higher in CUL4A-overexpressing cells. CUL4A overexpression increased the proliferation of cells as compared with control cells. After treatment with bafilomycin A1, proliferation was inhibited in both cell types, but the effects were more prominent in the cells overexpressing CUL4A. CUL4A promotes autophagy, and exhibits significantly higher autophagic flux which affects the proliferation of iCCA cells; these effects correlated with advance tumor stage and poor prognosis. Thus, targeting autophagy may be potentially therapeutic in iCCA.
CUL4A regulate the termination of autophagy in a physical process. However, the relationship between CUL4A and autophagy in cancer is unclear. We retrospectively investigated 99 intrahepatic cholangiocarcinoma (iCCA) cases. Whole sections were used for immunohistochemical analysis for p62, and LC3B expression. Q-score was defined as the sum of the labeling intensity and proportion. The cut-off point for immunoreactivity was set. CUL4A was overexpressed in cell lines and autophagy reflux was compared after manipulation. The iCCA cases with CUL4A overexpression had significantly higher prevalence of intact activated autophagy (42.4 vs. 15.2%; p = 0.003), which was significantly associated with advance tumor stage (34.1% vs. 15.4%; p = 0.032), less extensive necrosis (8.3 vs. 49.3%; p < 0.001), and shortened disease-free survival (mean, 19.6 vs. 65.5 months, p = 0.015). In vitro, iCCA cells with CUL4A overexpression significantly increased LC3II level as compared to the cells under basal condition. Although both cell types showed intact autophagy with increased LC3II expression after bafilomycin A1 treatment, the accumulation of LC3II was higher in CUL4A-overexpressing cells. CUL4A overexpression increased the proliferation of cells as compared with control cells. After treatment with bafilomycin A1, proliferation was inhibited in both cell types, but the effects were more prominent in the cells overexpressing CUL4A. CUL4A promotes autophagy, and exhibits significantly higher autophagic flux which affects the proliferation of iCCA cells; these effects correlated with advance tumor stage and poor prognosis. Thus, targeting autophagy may be potentially therapeutic in iCCA.
CUL4A regulate the termination of autophagy in a physical process. However, the relationship between CUL4A and autophagy in cancer is unclear. We retrospectively investigated 99 intrahepatic cholangiocarcinoma (iCCA) cases. Whole sections were used for immunohistochemical analysis for p62, and LC3B expression. Q-score was defined as the sum of the labeling intensity and proportion. The cut-off point for immunoreactivity was set. CUL4A was overexpressed in cell lines and autophagy reflux was compared after manipulation. The iCCA cases with CUL4A overexpression had significantly higher prevalence of intact activated autophagy (42.4 vs. 15.2%; = 0.003), which was significantly associated with advance tumor stage (34.1% vs. 15.4%; = 0.032), less extensive necrosis (8.3 vs. 49.3%; < 0.001), and shortened disease-free survival (mean, 19.6 vs. 65.5 months, = 0.015). , iCCA cells with CUL4A overexpression significantly increased LC3II level as compared to the cells under basal condition. Although both cell types showed intact autophagy with increased LC3II expression after bafilomycin A1 treatment, the accumulation of LC3II was higher in CUL4A-overexpressing cells. CUL4A overexpression increased the proliferation of cells as compared with control cells. After treatment with bafilomycin A1, proliferation was inhibited in both cell types, but the effects were more prominent in the cells overexpressing CUL4A. CUL4A promotes autophagy, and exhibits significantly higher autophagic flux which affects the proliferation of iCCA cells; these effects correlated with advance tumor stage and poor prognosis. Thus, targeting autophagy may be potentially therapeutic in iCCA.
Author You, Huey-Ling
Huang, Wan-Ting
Weng, Shao-Wen
Eng, Hock-Liew
Liu, Ting-Ting
AuthorAffiliation 1 Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung , Taiwan
3 Department of Medical Laboratory Science, I-Shou University, Kaohsiung , Taiwan
5 Department of Medical Laboratory Sciences and Biotechnology, Fooyin University, Kaohsiung , Taiwan
2 Department of Pathology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung , Taiwan
4 Department of Laboratory Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung , Taiwan
AuthorAffiliation_xml – name: 4 Department of Laboratory Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung , Taiwan
– name: 5 Department of Medical Laboratory Sciences and Biotechnology, Fooyin University, Kaohsiung , Taiwan
– name: 1 Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung , Taiwan
– name: 2 Department of Pathology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung , Taiwan
– name: 3 Department of Medical Laboratory Science, I-Shou University, Kaohsiung , Taiwan
Author_xml – sequence: 1
  givenname: Shao-Wen
  surname: Weng
  fullname: Weng, Shao-Wen
– sequence: 2
  givenname: Ting-Ting
  surname: Liu
  fullname: Liu, Ting-Ting
– sequence: 3
  givenname: Hock-Liew
  surname: Eng
  fullname: Eng, Hock-Liew
– sequence: 4
  givenname: Huey-Ling
  surname: You
  fullname: You, Huey-Ling
– sequence: 5
  givenname: Wan-Ting
  surname: Huang
  fullname: Huang, Wan-Ting
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34257560$$D View this record in MEDLINE/PubMed
BookMark eNpdkUtr3DAURkVJaV7dd1UE3WTjqR62HpvCMPQRGOgQkmURsnw9VvBIrmQX5t_HZtKQdqULOnyce79LdBZiAIQ-ULLiXOnPQ0ywYoTRlSBM0vINuqAVZwVTRJ69ms_RZc6PhBAptHiHznnJKlkJcoF-racxDp3dH_Gut8eMLb6LPWAf8NgB3jxsy3VxB70docG7GBPepbgPMfuMY4tvw5hsB4MdvcObLvY27H10Njkf4sFeo7et7TO8f36v0MO3r_ebH8X25_fbzXpbOC7lWIBWDS15KWtBm1maOMWdrZXWlQIpWMNBtbamvGFAKtsq6ohual1aTktBNL9CX065w1QfoHGwaPVmSP5g09FE682_P8F3Zh__GMUEo4rMATfPASn-niCP5uCzg37eB-KUDasqWslSCzGjn_5DH-OUwryeWY6qCGNyMfr42uhF5e_lZ4CcAJdizgnaF4QSs5RrlnLNUq45lcufAHexl0o
Cites_doi 10.1002/1873-3468.12172
10.1172/JCI20039
10.1111/jcmm.12811
10.1016/j.bbrc.2016.10.114
10.1093/carcin/bgt063
10.1111/j.1582-4934.2009.00971.x
10.1038/cddis.2013.350
10.1158/1078-0432.CCR-11-1282
10.3892/ijmm.2018.3540
10.1016/j.devcel.2014.11.013
10.3892/or.2015.4324
10.1186/bcr2456
10.1038/nrd2974
10.18632/oncotarget.17554
10.1038/bjc.2014.355
10.1038/onc.2016.333
10.1098/rsob.130217
10.1371/journal.pone.0145388
10.1007/s10495-015-1176-3
10.1158/0008-5472.CAN-13-2182
10.1158/0008-5472.CAN-04-2598
10.1126/science.1193497
10.1073/pnas.2436255100
10.1371/journal.pone.0074407
10.1186/s12885-017-3389-z
10.4081/ejh.2015.2481
10.1007/s00109-012-0885-0
10.4161/auto.26398
10.1056/NEJMc1303158
10.1038/s41388-017-0046-6
10.1053/jhep.2002.33683
ContentType Journal Article
Copyright Copyright © 2021 Weng, Liu, Eng, You and Huang.
2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright © 2021 Weng, Liu, Eng, You and Huang. 2021 Weng, Liu, Eng, You and Huang
Copyright_xml – notice: Copyright © 2021 Weng, Liu, Eng, You and Huang.
– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Copyright © 2021 Weng, Liu, Eng, You and Huang. 2021 Weng, Liu, Eng, You and Huang
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7RV
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
KB0
M0S
NAPCQ
PHGZM
PHGZT
PIMPY
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
5PM
DOI 10.3389/pore.2021.602714
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
ProQuest Nursing and Allied Health Journals - PSU access expires 11/30/25.
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Health & Medical Collection
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Central
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef

MEDLINE - Academic
Publicly Available Content Database
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Weng et al
EISSN 1532-2807
ExternalDocumentID PMC8262180
34257560
10_3389_pore_2021_602714
Genre Journal Article
GeographicLocations United States--US
Switzerland
Japan
GeographicLocations_xml – name: Switzerland
– name: United States--US
– name: Japan
GrantInformation_xml – fundername: Ministry of Science, Technology and Research
GroupedDBID ---
.VR
06C
06D
0R~
123
1N0
203
29O
29~
2J2
2KG
2KM
2LR
2~H
30V
4.4
408
40D
40E
53G
5VS
67N
67Z
6NX
7RV
7X7
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
9T4
AAAVM
AABHQ
AAJKR
AARTL
AATVU
AAWCG
AAYIU
AAYQN
AAYXX
ABDZT
ABFTV
ABJNI
ABJOX
ABKCH
ABMNI
ABNWP
ABPLI
ABQBU
ABTEG
ABTHY
ABTMW
ABUWG
ABXPI
ACGFS
ACHXU
ACKNC
ACMLO
ACOKC
ACOMO
ACPRK
ACSNA
ADBBV
ADHHG
ADHIR
ADKPE
ADRFC
ADURQ
ADYFF
ADZKW
AEGAL
AEGNC
AEJHL
AEJRE
AENEX
AEOHA
AEPYU
AETLH
AEXYK
AFBBN
AFKRA
AFRAH
AFWTZ
AFZKB
AGAYW
AGDGC
AGQMX
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHKAY
AHMBA
AHYZX
AIIXL
AILAN
AITGF
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMYQR
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BENPR
CCPQU
CITATION
CS3
CSCUP
DU5
E3Z
EBD
EBS
EIOEI
EMOBN
ESBYG
EX3
F5P
FDB
FERAY
FFXSO
FNLPD
FRRFC
FWDCC
FYUFA
G-Q
G-Y
G-Z
GGRSB
GJIRD
GNWQR
GQ7
GROUPED_DOAJ
HF~
HMCUK
HMJXF
HRMNR
HZ~
IJ-
IXC
IXD
I~X
I~Z
J-C
J0Z
JBSCW
KOV
KPH
MA-
NAPCQ
NB0
NQ-
NQJWS
O93
O9I
O9J
OK1
PF0
PGMZT
PHGZM
PHGZT
PIMPY
PROAC
QOK
QOR
QOS
R89
R9I
RPM
RSV
S16
S27
S3A
S3B
SAP
SBL
SDH
SHX
SISQX
SOJ
SPISZ
SSXJD
STPWE
SV3
SZN
T13
TSG
TSK
TSV
TUC
U2A
UG4
UKHRP
UOJIU
UTJUX
VC2
W48
WK8
WOW
YLTOR
Z45
ZMTXR
ZOVNA
~A9
--K
-Y2
0VY
1B1
1RT
1~5
2JY
2VQ
2WC
4G.
7-5
88E
AAEDT
AAFWJ
AAIAL
AALRI
AANXM
AAQFI
AAQXK
AARHV
AAXUO
AAYTO
AAYZH
ABMAC
ABMOR
ABWVN
ACRPL
ADMUD
ADNMO
ADYPR
AEBTG
AFGCZ
AFLOW
AFPKN
AGJBK
AHSBF
AITUG
AJBLW
BDATZ
BGNMA
BKEYQ
BPHCQ
BVXVI
CAG
CGR
COF
CUY
CVF
ECM
EIF
EJD
EN4
EO8
EO9
EP2
FEDTE
FGOYB
FINBP
FSGXE
H13
HVGLF
IHE
M1P
M41
M4Y
NPM
NU0
O9-
P6G
PQQKQ
PSQYO
R2-
RHV
RIG
ROL
RPZ
S1Z
SDG
SSZ
TR2
UHS
UZXMN
VFIZW
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PPXIY
PQEST
PQUKI
7X8
PUEGO
~HD
5PM
ID FETCH-LOGICAL-c377t-e98d14347b61d1530c83cab89958e762d3e8fab13d2e05af81c09db94a3146093
IEDL.DBID 7X7
ISSN 1532-2807
1219-4956
IngestDate Thu Aug 21 13:47:55 EDT 2025
Sun Sep 28 10:24:28 EDT 2025
Mon Jul 14 09:25:45 EDT 2025
Thu Apr 03 07:06:44 EDT 2025
Tue Jul 01 02:53:21 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords CUL4A
LC3II
autophagy
prognosis
intrahepatic cholangiocarcinoma
Language English
License Copyright © 2021 Weng, Liu, Eng, You and Huang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c377t-e98d14347b61d1530c83cab89958e762d3e8fab13d2e05af81c09db94a3146093
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
These authors have contributed equally to this work
Edited by: László Kopper, Semmelweis University, Hungary
OpenAccessLink https://www.proquest.com/docview/2575802279?pq-origsite=%requestingapplication%
PMID 34257560
PQID 2575802279
PQPubID 5225552
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8262180
proquest_miscellaneous_2551574966
proquest_journals_2575802279
pubmed_primary_34257560
crossref_primary_10_3389_pore_2021_602714
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-02-23
PublicationDateYYYYMMDD 2021-02-23
PublicationDate_xml – month: 02
  year: 2021
  text: 2021-02-23
  day: 23
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Dordrecht
PublicationTitle Pathology oncology research
PublicationTitleAlternate Pathol Oncol Res
PublicationYear 2021
Publisher Frontiers Media SA
Frontiers Media S.A
Publisher_xml – name: Frontiers Media SA
– name: Frontiers Media S.A
References Wang (B8) 2014; 74
Lazova (B23) 2012; 18
Nag (B2) 2004; 64
Singh (B11) 2018; 37
Li (B19) 2013; 34
Niklaus (B18) 2017; 8
Yu (B28) 2018; 41
Hung (B30) 2015; 34
Chen (B3) 1998; 58
Sui (B31) 2013; 4
Choi (B12) 2013; 368
Schlafli (B15) 2015; 59
Peng (B25) 2013; 8
Liu (B9) 2015; 10
Huang (B10) 2017; 17
Melchor (B7) 2009; 11
Ren (B6) 2012; 90
Peng (B24) 2013; 9
Hung (B5) 2011; 15
Antonioli (B14) 2014; 31
Rabinowitz (B13) 2010; 330
Yue (B22) 2003; 100
Han (B27) 2016; 480
Copeland (B32) 2009; 8
Mowers (B26) 2017; 36
Hung (B29) 2016; 20
Sharma (B1) 2014; 4
Liu (B17) 2014; 111
Kim (B20) 2016; 590
Falasca (B16) 2015; 20
Hsieh (B33) 2016; 6
Qu (B21) 2003; 112
Yasui (B4) 2002; 35
References_xml – volume: 590
  start-page: 1365
  year: 2016
  ident: B20
  article-title: Uncoordinated 51-like kinase 2 signaling pathway regulates epithelial-mesenchymal transition in A549 lung cancer cells
  publication-title: FEBS Lett.
  doi: 10.1002/1873-3468.12172
– volume: 112
  start-page: 1809
  year: 2003
  ident: B21
  article-title: Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI20039
– volume: 20
  start-page: 1295
  year: 2016
  ident: B29
  article-title: Knockdown of cullin 4A inhibits growth and increases chemosensitivity in lung cancer cells
  publication-title: J. Cell Mol. Med.
  doi: 10.1111/jcmm.12811
– volume: 480
  start-page: 675
  year: 2016
  ident: B27
  article-title: CUL4A functions as an oncogene in ovarian cancer and is directly regulated by miR-494
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2016.10.114
– volume: 34
  start-page: 1343
  year: 2013
  ident: B19
  article-title: Autophagy promotes hepatocellular carcinoma cell invasion through activation of epithelial-mesenchymal transition
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgt063
– volume: 15
  start-page: 350
  year: 2011
  ident: B5
  article-title: Cul4A is an oncogene in malignant pleural mesothelioma
  publication-title: J. Cell Mol. Med.
  doi: 10.1111/j.1582-4934.2009.00971.x
– volume: 4
  start-page: e838
  year: 2013
  ident: B31
  article-title: Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment
  publication-title: Cell Death Dis.
  doi: 10.1038/cddis.2013.350
– volume: 18
  start-page: 370
  year: 2012
  ident: B23
  article-title: Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis, and poor outcome
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-11-1282
– volume: 41
  start-page: 3147
  year: 2018
  ident: B28
  article-title: miR377 targets CUL4A and regulates metastatic capability in ovarian cancer
  publication-title: Int. J. Mol. Med.
  doi: 10.3892/ijmm.2018.3540
– volume: 31
  start-page: 734
  year: 2014
  ident: B14
  article-title: AMBRA1 interplay with cullin E3 ubiquitin ligases regulates autophagy dynamics
  publication-title: Dev. Cell
  doi: 10.1016/j.devcel.2014.11.013
– volume: 34
  start-page: 3187
  year: 2015
  ident: B30
  article-title: Knockdown of Cul4A increases chemosensitivity to gemcitabine through upregulation of TGFBI in lung cancer cells
  publication-title: Oncol. Rep.
  doi: 10.3892/or.2015.4324
– volume: 11
  start-page: R86
  year: 2009
  ident: B7
  article-title: Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes
  publication-title: Breast Cancer Res.
  doi: 10.1186/bcr2456
– volume: 8
  start-page: 724
  year: 2009
  ident: B32
  article-title: Protein methyltransferases as a target class for drug discovery
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/nrd2974
– volume: 8
  start-page: 54604
  year: 2017
  ident: B18
  article-title: Expression analysis of LC3B and p62 indicates intact activated autophagy is associated with an unfavorable prognosis in colon cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.17554
– volume: 58
  start-page: 3677
  year: 1998
  ident: B3
  article-title: The human homologue for the Caenorhabditis elegans cul-4 gene is amplified and overexpressed in primary breast cancers
  publication-title: Cancer Res.
– volume: 111
  start-page: 944
  year: 2014
  ident: B17
  article-title: Prognostic significance of p62/SQSTM1 subcellular localization and LC3B in oral squamous cell carcinoma
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2014.355
– volume: 36
  start-page: 1619
  year: 2017
  ident: B26
  article-title: Autophagy in cancer metastasis
  publication-title: Oncogene
  doi: 10.1038/onc.2016.333
– volume: 4
  start-page: 130217
  year: 2014
  ident: B1
  article-title: CUL4A ubiquitin ligase: a promising drug target for cancer and other human diseases
  publication-title: Open Biol.
  doi: 10.1098/rsob.130217
– volume: 10
  start-page: e0145388
  year: 2015
  ident: B9
  article-title: Recurrent amplification at 13q34 targets at CUL4A, IRS2, and TFDP1 as an independent adverse prognosticator in intrahepatic cholangiocarcinoma
  publication-title: Plos One.
  doi: 10.1371/journal.pone.0145388
– volume: 20
  start-page: 1577
  year: 2015
  ident: B16
  article-title: AMBRA1 and SQSTM1 expression pattern in prostate cancer
  publication-title: Apoptosis
  doi: 10.1007/s10495-015-1176-3
– volume: 74
  start-page: 520
  year: 2014
  ident: B8
  article-title: CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-13-2182
– volume: 64
  start-page: 8152
  year: 2004
  ident: B2
  article-title: Cul4A physically associates with MDM2 and participates in the proteolysis of p53
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-04-2598
– volume: 6
  start-page: 1661
  year: 2016
  ident: B33
  article-title: EZH2 inhibitors transcriptionally upregulate cytotoxic autophagy and cytoprotective unfolded protein response in human colorectal cancer cells
  publication-title: Am. J. Cancer Res.
– volume: 330
  start-page: 1344
  year: 2010
  ident: B13
  article-title: Autophagy and metabolism
  publication-title: Science
  doi: 10.1126/science.1193497
– volume: 100
  start-page: 15077
  year: 2003
  ident: B22
  article-title: Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor
  publication-title: Proc. Natl. Acad. Sci. USA.
  doi: 10.1073/pnas.2436255100
– volume: 8
  start-page: e74407
  year: 2013
  ident: B25
  article-title: Promoting colonization in metastatic HCC cells by modulation of autophagy
  publication-title: PloS One
  doi: 10.1371/journal.pone.0074407
– volume: 17
  start-page: 395
  year: 2017
  ident: B10
  article-title: CUL4A overexpression as an independent adverse prognosticator in intrahepatic cholangiocarcinoma
  publication-title: BMC Cancer.
  doi: 10.1186/s12885-017-3389-z
– volume: 59
  start-page: 2481
  year: 2015
  ident: B15
  article-title: Reliable LC3 and p62 autophagy marker detection in formalin fixed paraffin embedded human tissue by immunohistochemistry
  publication-title: Eur. J. Histochem.
  doi: 10.4081/ejh.2015.2481
– volume: 90
  start-page: 1121
  year: 2012
  ident: B6
  article-title: Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer
  publication-title: J. Mol. Med.
  doi: 10.1007/s00109-012-0885-0
– volume: 9
  start-page: 2056
  year: 2013
  ident: B24
  article-title: Autophagy inhibition suppresses pulmonary metastasis of HCC in mice via impairing anoikis resistance and colonization of HCC cells
  publication-title: Autophagy
  doi: 10.4161/auto.26398
– volume: 368
  start-page: 651
  year: 2013
  ident: B12
  article-title: Autophagy in human health and disease
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMc1303158
– volume: 37
  start-page: 1142
  year: 2018
  ident: B11
  article-title: Dual role of autophagy in hallmarks of cancer
  publication-title: Oncogene
  doi: 10.1038/s41388-017-0046-6
– volume: 35
  start-page: 1476
  year: 2002
  ident: B4
  article-title: TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas
  publication-title: Hepatology
  doi: 10.1053/jhep.2002.33683
SSID ssj0007696
Score 2.234861
Snippet CUL4A regulate the termination of autophagy in a physical process. However, the relationship between CUL4A and autophagy in cancer is unclear. We...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 602714
SubjectTerms Antibodies
Autophagy
Bile Duct Neoplasms - metabolism
Bile Duct Neoplasms - mortality
Bile Duct Neoplasms - pathology
Biomarkers, Tumor - metabolism
Cancer
Cholangiocarcinoma
Cholangiocarcinoma - metabolism
Cholangiocarcinoma - mortality
Cholangiocarcinoma - pathology
Cloning
Cullin Proteins - metabolism
Female
Follow-Up Studies
Gene expression
Humans
Male
Medical prognosis
Metabolism
Metastasis
Middle Aged
Prognosis
Prostate
Proteins
Retrospective Studies
Society Journal Archive
Survival analysis
Survival Rate
Tumor Cells, Cultured
Tumorigenesis
Title Autophagy Plays a Role in the CUL4A-Related Poor Prognosis of Intrahepatic Cholangiocarcinoma
URI https://www.ncbi.nlm.nih.gov/pubmed/34257560
https://www.proquest.com/docview/2575802279
https://www.proquest.com/docview/2551574966
https://pubmed.ncbi.nlm.nih.gov/PMC8262180
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEBZtAqWX0vQVN8miQi89qLEiybJPZbMkpKUJS-jCXorRa5OF1Nru45B_nxnZu-m20LOFZc9IM9-nGc0Q8lHbYH0hDFM8eCY9lrwNlWLKuGBM0Goi8e7w5VVxMZLfxmrcHbgturTKtU1MhtpHh2fkx7C0VJnq3X2Z_WbYNQqjq10LjadklwMSwdYNerwhXEDRU38uDruSIRFow5RAyqrjGdaIBOLPPxdAzLjcdkv_YM2_Uyb_8EHnL8mLDjzSfqvtPfIkNK_Is8suPP6a_OyvsE6Aubmnwztzv6CGXse7QKcNBZxHB6Pvss9S-lvwdBjjnA7nETPtpgsaJ_QrTnobMMfa0QGS3uZmCr5uDm-Pv8wbMjo_-zG4YF3_BOaE1ksWqtIDHJLaFtyDZctdKZyxwLBUGcAIehHKibFc-JOQKzMpucsrbytpBNjPvBJvyU4Tm7BPKPfWuBMnfRHA5Ve2Kk2Ra-ektAAhhMrIp7X46llbJqMGeoGirlHUNYq6bkWdkcO1fOtuwyzqR_Vm5MPmMSx1jF-YJsQVjgHwpSUQtIy8a9WxmUyg7QH0lhG9pajNACyjvf2kmd6mctpAsADn5O___1kH5Dn-Q7rNLg7JznK-CkeAR5a2lxZdj-yenl0Nr3uJ1ffSsdED6bbjUw
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB5VRQIuiHddCiwSHDgs9WPttQ9VFQWqhCZVhBopF2T2lTZSsdM8hPKn-hs7Y8eBgMSt51157dl5fJ9ndhbgvdRO2yRSPA6c5cJSy1uXxTxWxinlZDwWdHa4f5Z0huLrKB7twE1zFobKKhufWDlqWxr6R36IqhWnVb-74-k1p1ujKLvaXKFRq8WpW_1CyjY_6n7G_f0Qhidfztsdvr5VgJtIygV3WWoRJAipk8CivfsmjYzSyDvi1KFrsJFLx0oHkQ2dH6txGhg_szoTKkKvUjVfQpd_T1CKEe1HjjYEz5dJdR9YgF6AE_Go06JIArPDKfWkDDGgfkqQCAZiOwz-g23_LtH8I-adPIZHa7DKWrV2PYEdVzyF-_11Ov4ZfG8tqS-BulixwZVazZli38orxyYFQ1zJ2sOeaPGq3M5ZNijLGRvMSqrsm8xZOWZdWvTSUU23YW0i2cXFBGPrDJ9e_lTPYXgnkn0Bu0VZuD1ggdXKhEbYxCHEyHSWqsSXxgihEbJEsQcfG_Hl07otR450hkSdk6hzEnVei9qDg0a--dpA5_lvdfLg3WYYTYvyJapw5ZLmINiTAgmhBy_r7dgsFpGvQ7TogdzaqM0Eatu9PVJMLqv23UjoEFf5-_9_rbfwoHPe7-W97tnpK3hI31OdpI8OYHcxW7rXiIUW-k2lgAx-3LXG3wLaZhvC
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB5VRaq4IN64FFgkOHAwsb1rr31AKEqJGvpQhIiUCzL7chup2CEPofw1fh0zfgQCEreed-W1Z2dnvs8zOwPwSmqnbcKVH4fO-sJSyVuXxX6sjFPKybgQdHf4_CI5mYiP03i6Bz-7uzCUVtnZxNpQ28rQP_Ieqlac1vXuekWbFjE-Hr6ff_epgxRFWrt2Go2KnLrND6Rvy3ejY9zr11E0_PB5cOK3HQZ8w6Vc-S5LLQIGIXUSWjz7gUm5URo5SJw6NBOWu7RQOuQ2ckGsijQ0QWZ1JhRHC1MXYkLzf0tyIahthJxuyV4gk7o3WIgWwScS0oRIkRBmvTnVp4zQub5NkBSGYtcl_oNz_07X_MP_De_CnRa4sn6jafdgz5X34eC8Dc0_gC_9NdUoUJcbNr5WmyVT7FN17disZIgx2WByJvp-nXrnLBtX1YKNFxVl-c2WrCrYiBa9cpTfbdiACHd5OUM_u8CnV9_UQ5jciGQfwX5Zle4JsNBqZSIjbOIQbmQ6S1USSGOE0AhfeOzBm058-bwp0ZEjtSFR5yTqnESdN6L24KiTb94e1mX-W7U8eLkdxmNGsRNVumpNcxD4SYHk0IPHzXZsF-Nk9xA5eiB3Nmo7gUp4746Us6u6lDeSO8RYweH_X-sFHKCu52eji9OncJs-p75Uz49gf7VYu2cIi1b6ea1_DL7etML_AuZrH_U
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Autophagy+Plays+a+Role+in+the+CUL4A-Related+Poor+Prognosis+of+Intrahepatic+Cholangiocarcinoma&rft.jtitle=Pathology+oncology+research&rft.au=Weng%2C+Shao-Wen&rft.au=Liu%2C+Ting-Ting&rft.au=Eng%2C+Hock-Liew&rft.au=You%2C+Huey-Ling&rft.date=2021-02-23&rft.pub=Frontiers+Media+S.A&rft.issn=1219-4956&rft.eissn=1532-2807&rft.volume=27&rft_id=info:doi/10.3389%2Fpore.2021.602714&rft_id=info%3Apmid%2F34257560&rft.externalDocID=PMC8262180
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1532-2807&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1532-2807&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1532-2807&client=summon